Cytos Biotechnology soars on results of asthma-drug study – FierceBiotech

Cytos Biotechnology soars on results of asthma-drug study
FierceBiotech
After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning …
Cytos Rises After Asthma Drug Succeeds in Trial: Zurich MoverBloomberg
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study …PR Newswire (press release)

all 3 news articles »